Form 8-K - Current report:
SEC Accession No. 0001641172-25-006009
Filing Date
2025-04-24
Accepted
2025-04-24 16:27:20
Documents
17
Period of Report
2025-04-23
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 44050
2 ex4-1.htm EX-4.1 135853
3 ex4-2.htm EX-4.2 113397
4 ex10-1.htm EX-10.1 61399
5 ex99-1.htm EX-99.1 15339
  Complete submission text file 0001641172-25-006009.txt   628059

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE ensc-20250423.xsd EX-101.SCH 3012
7 XBRL LABEL FILE ensc-20250423_lab.xml EX-101.LAB 34240
8 XBRL PRESENTATION FILE ensc-20250423_pre.xml EX-101.PRE 24163
19 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3689
Mailing Address 7946 IVANHOE AVENUE SUITE 201 LA JOLLA CA 92037
Business Address 7946 IVANHOE AVENUE SUITE 201 LA JOLLA CA 92037 (858) 263-4196
Ensysce Biosciences, Inc. (Filer) CIK: 0001716947 (see all company filings)

EIN.: 822755287 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38306 | Film No.: 25867713
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)